Inactive Instrument

News InterMune Inc

Stocks

US45884X1037

Biotechnology & Medical Research

End-of-day quote Nasdaq
- ^USD	-

16/14/16	CHUGAI PHARMACEUTICAL : Roche's $8 billion InterMune buy not a signal for more big deals	RE
04/14/04	Roche : rules out mega deals, open to smaller ones - paper	RE

All News

Mentions Relevance

02/14/02	InterMune : Announces Effective Date of Make Whole Fundamental Change and Offer to Purchase to Holders of 2.50% Senior Convertible Notes Due 2018	PU
20/14/20	InterMune : Reports Memorandum of Understanding in Connection with Consolidated Delaware Action	PR
05/14/05	InterMune : Announces Anticipated Fundamental Change for 5.00% Convertible Senior Notes Due 2015	PR
28/14/28	InterMune : Stockholders Encouraged to Contact Securities Law Firm about Takeover	PR
27/14/27	InterMune : INVESTOR ALERT – InterMune, Inc.: The Law Offices of Vincent Wong Investigates the Sale of InterMune, Inc. to Roche Holding AG	BU
26/14/26	InterMune : INVESTOR ALERT: Levi & Korsinsky, LLP Announces Investigation of InterMune, Inc. and Its Board of Directors In Connection With the Sale of the Company to Roche Holding AG -- ITMN	PR
26/14/26	InterMune : Ryan & Maniskas, LLP : Announces Investigation of InterMune, Inc.	PR
26/14/26	InterMune : INVESTOR ALERT - InterMune, Inc.: The Law Offices of Vincent Wong Investigates the Sale of InterMune, Inc. to Roche Holding AG - ITMN	PR
25/14/25	InterMune : Newman Ferrara LLP : Announces Investigation of InterMune, Inc.	BU
25/14/25	InterMune : INVESTOR ALERT: Levi & Korsinsky, LLP Announces Investigation of InterMune, Inc. and Its Board of Directors In Connection With the Sale of the Company to Roche Holding AG	BU
25/14/25	InterMune : Law Firm Kirby McInerney LLP Investigating Potential Claims on Behalf of InterMune, Inc. Stockholders	BU
25/14/25	InterMune : INVESTOR ALERT: Levi & Korsinsky, LLP Announces Investigation of InterMune, Inc. and Its Board of Directors In Connection With the Sale of the Company to Roche Holding AG	BU
07/14/07	InterMune : Reports Second Quarter 2014 Financial Results and Business Highlights	PU
28/14/28	InterMune : to Release Second Quarter Financial Results on August 6	PR
17/14/17	InterMune : Receives FDA Breakthough Therapy Designation For Pirfenidone, An Investigational Treatment For IPF	PR
27/14/27	InterMune : Announces Resubmission Of NDA For Pirfenidone For The Treatment Of Patients With IPF	PU
21/14/21	InterMune : Announces Additional Pirfenidone Data in Idiopathic Pulmonary Fibrosis	PU
19/14/19	InterMune : Phase 3 ASCEND Study of Pirfenidone in Idiopathic Pulmonary Fibrosis Presented at American Thoracic Society (ATS) and Published in New England Journal of Medicine	PU
16/14/16	InterMune : Announces Expanded Access Program for Pirfenidone to Treat Idiopathic Pulmonary Fibrosis (IPF) in the United States	PR
12/14/12	InterMune : Announces Upcoming Data Presentations at 2014 American Thoracic Society Meeting	PU
02/14/02	InterMune : Reports First Quarter 2014 Financial Results, Clinical Development and Business Highlights	PU
23/14/23	InterMune : To Release First Quarter Financial Results On May 1	PR
14/14/14	InterMune : Announces Pricing of Public Offering of 7,500,000 Shares of Common Stock	PR
13/14/13	InterMune Inc : InterMune Announces Proposed Public Offering of Common Stock	PR
10/14/10	InterMune Inc : Cannabis & Biotech Advancers Forging Ahead - Company Contracts With One of The Oldest Marijuana Dispensaries in California	PR